查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2012144

糖尿病治療市場：2026-2032年全球市場預測（按藥物類別、患者類型、給藥途徑、治療方法、分銷管道和最終用戶分類）

Antidiabetic Drugs Market by Drug Class, Patient Type, Route Of Administration, Therapy Type, Distribution Channel, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，糖尿病藥物市場價值將達到 1,017.2 億美元，到 2026 年將成長至 1,117.1 億美元，到 2032 年將達到 2,174.9 億美元，複合年成長率為 11.46%。

主要市場統計數據
基準年 2025 1017.2億美元
預計年份：2026年 1117.1億美元
預測年份 2032 2174.9億美元
複合年成長率 (%) 11.46%

對不斷發展的抗糖尿病藥物趨勢進行簡要概述，重點關注臨床進展、患者需求和商業性發展。

糖尿病治療領域正處於持續演變之中，其驅動力來自臨床創新、不斷變化的患者期​​望以及醫療政策重點的調整。本文概述了抗糖尿病治療的關鍵臨床類別、新型生物製藥與先進口服藥物的交叉領域，以及相關人員在研發、採購和交付各階段所面臨的營運挑戰。透過將目前進展置於更廣泛的醫療服務體系中，本文重點闡述了治療方法選擇如何日益受到作用機制、病患合併症和長期療效目標差異的影響。

精準醫療、數位療法和基於價值的支付模式正在推動糖尿病照護發生變革性轉變，惠及所有相關人員。

科學突破和系統性創新正在共同推動糖尿病治療的變革，並改變臨床路徑和商業模式。精準醫療和腸促胰素生物製藥拓展了治療選擇，而胰島素類似物和給藥裝置的迭代改進顯著提升了安全性和患者便利性。同時，數位化療法、遠距監測和整合式醫療平台的日益成熟，使得更持續的管理模式成為可能，這些技術也正逐步融入標準診療流程。

對 2025 年美國關稅政策調整對供應鏈、定價和准入途徑的連鎖反應進行全面分析。

貿易和關稅框架的政策調整可能會在全球醫藥供應鏈中引發新的摩擦，其中已宣布的2025年調整將對營運和策略產生直接影響。對於依賴跨國採購生產活性藥物成分、初級包裝或成品的企業而言，關稅變化可能會改變成本結構，引發採購優先事項的重新分配，並對生產擴張計畫造成壓力。因此，供應鏈經理和採購負責人正日益重視供應商多元化、離岸外包和庫存策略，以減輕關稅對價格波動的影響。

關鍵細分洞察，用於解讀藥物類別、患者人口統計特徵、給藥途徑、治療模式、通路和最終用戶需求。

建構精細的市場細分框架對於解讀整個抗糖尿病藥物市場的治療趨勢和競爭格局至關重要。本研究依藥物類別分析市場，重點在於胰島素和口服藥物。胰島素進一步細分為胰島素類似物和人類胰島素，其中胰島素類似物細分市場將根據其不同的臨床應用和裝置相容性，進一步細分為長效、速效和超長效製劑。同時，口服藥物類別進一步細分為雙胍類、DPP-4抑制劑、GLP-1受體促效劑、SGLT-2抑制劑和磺醯尿素類，每種藥物均需考慮其不同的作用機制和安全性與有效性之間的權衡。

美洲、歐洲、中東和非洲以及亞太地區的區域性和細微市場趨勢，重點在於進入和創新的促進因素。

區域差異對全球治療方法的採納、監管時間表和報銷框架都產生了顯著影響。在美洲，醫療保健系統涵蓋了公私合作模式和主要由私人保險公司運營的模式，這種多樣性影響著處方藥的上市談判、市場准入管道以及創新產品的推廣速度。在該地區運營的製造商通常優先考慮產生真實世界數據 (RWE)，並與保險公司合作，以證明其產品在不同的報銷條件下具有價值。

策略性企業趨勢揭示領先製藥和生技公司的研發重點、合作模式和競爭定位

糖尿病治療領域的主要企業正透過整合強大的臨床研發管線、策略合作夥伴關係以及對以患者為中心的技術的投資來脫穎而出。研發重點日益集中在那些除了血糖控制之外還能帶來其他益處（例如心血管和腎臟保護）的藥物，而研發策略則側重於改進藥物配方，以提高患者的用藥依從性並減輕治療負擔。製藥開發商與數位醫療公司之間的合作正在加速將遠端監測、用藥依從性支援和數據分析整合到治療方案中，從而形成能夠更好地應對慢性疾病管理的綜合解決方案。

為行業領導者提供切實可行的建議，以加快部署、增強供應鏈韌性並最佳化以患者為中心的護理路徑。

產業領導者應採取一系列切實可行的措施，以增強競爭韌性並加速患者群體治療效果的提升。首先，應整合實證策略和商業計劃，並設計臨床開發項目以支持與保險公司的對話和長期療效評估。透過將臨床終點與實際應用結合，企業可以縮短報銷時間並提升處方集的排名。其次，應實現供應鏈多元化，並投資制定短期緊急時應對計畫，以降低關稅變化、地緣政治格局變化和生產中斷等風險。

一套穩健的調查方法，描述了為確保資料來源、分析框架、檢驗過程和方法的嚴謹性而採取的措施。

本分析的調查方法透過整合多源證據、專家檢驗和迭代分析審查，確保了研究的嚴謹性和有效性。主要資訊來源包括同行評審的臨床文獻、監管指導文件和公開的臨床試驗註冊數據，這些數據被整合起來，以揭示治療機制、安全性特徵和不斷變化的終點指標。此外，產業資訊披露和公司備案文件也被作為補充​​，用於了解策略舉措和技術投資。

結合臨床趨勢、政策影響、細分市場洞察以及對相關人員。

這項綜合分析結合了臨床創新、政策趨勢、市場區隔和區域差異，描繪出一幅現代抗糖尿病療法的完整整體情況。新興生物製藥和新一代胰島素製劑正在重塑治療模式，而數位醫療和基於價值的報銷模式的融合正在改變實證醫學的產生方式和治療方法的採購方式。同時，關稅和貿易政策的變化如同營運壓力測試，暴露了供應鏈的脆弱性，並迫使採購和分銷環節進行策略調整。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 糖尿病治療市場：依藥物類別分類

  • 胰島素
    • 胰島素類似物
      • 長效型
      • 快速起效
      • 超長效
    • 人類胰島素
  • 口服藥物
    • 雙胍類藥物
    • DPP-4抑制劑
    • GLP-1受體促效劑
    • SGLT-2抑制劑
    • 磺醯尿素類藥物

第9章：依患者類型分類的糖尿病藥物市場

  • 妊娠糖尿病
  • 糖尿病前期
  • 1型糖尿病
  • 2型糖尿病

第10章：糖尿病治療市場：依給藥途徑分類

  • 口服
  • 腸外

第11章 糖尿病藥物市場依治療方法

  • 聯合治療
  • 單藥治療

第12章 糖尿病藥物市場：依分銷管道分類

  • 離線
  • 線上

第13章 糖尿病治療市場：依最終使用者分類

  • 診所
  • 居家照護
  • 醫院

第14章 糖尿病治療市場：依地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第15章 糖尿病藥物市場：依類別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第16章 糖尿病藥物市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第17章：美國糖尿病治療市場

第18章：中國糖尿病治療藥物市場

第19章 競爭情勢

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alkem Laboratories Ltd.
  • Aristo Pharmaceuticals Pvt. Ltd.
  • Astellas Pharma Inc.
  • AstraZeneca PLC
  • Biocon Limited
  • Boehringer Ingelheim International GmbH
  • Cadila Pharmaceuticals Limited
  • Cipla Limited
  • Dr. Reddy's Laboratories
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Glenmark Pharmaceuticals Ltd.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Mankind Pharma Ltd.
  • Merck KGaA
  • Novo Nordisk A/S
  • Oramed Pharmaceuticals Inc.
  • Pfizer Inc.
  • PHC Holdings Corporation
  • Sanofi SA
  • Takeda Pharmaceutical Company Limited
  • Teva Pharmaceutical Industries Ltd.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
Product Code: MRR-437896AA366F

The Antidiabetic Drugs Market was valued at USD 101.72 billion in 2025 and is projected to grow to USD 111.71 billion in 2026, with a CAGR of 11.46%, reaching USD 217.49 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 101.72 billion
Estimated Year [2026] USD 111.71 billion
Forecast Year [2032] USD 217.49 billion
CAGR (%) 11.46%

A concise introduction to the evolving antidiabetic therapeutics landscape highlighting clinical advances, patient needs, and commercial dynamics

The therapeutic landscape for diabetes is undergoing a period of sustained evolution driven by clinical innovation, changing patient expectations, and shifting health policy priorities. This introduction frames the critical clinical categories of antidiabetic therapy, the intersection of novel biologics and advanced oral agents, and the operational pressures that stakeholders face across development, procurement, and care delivery. By situating current advances within a broader continuum of care, the narrative highlights how therapeutic choices are increasingly informed by mechanistic differentiation, patient comorbidities, and long-term outcome objectives.

Moreover, contemporary decision-making is shaped by digital health adoption, real-world evidence generation, and tighter regulatory scrutiny of safety and value. As a result, manufacturers, payers, and providers are required to balance speed of innovation with demonstrable improvements in adherence, glycemic control, and complication prevention. The following analysis is intended to orient readers to these converging forces and to provide a concise foundation for the deeper thematic sections that follow, enabling informed interpretation of subsequent insights on segmentation, regional dynamics, policy impacts, and strategic responses.

Transformational shifts reshaping diabetes care driven by precision medicines, digital therapeutics, and value-based payment models across stakeholders

Diabetes care is being transformed by a combination of scientific breakthroughs and system-level innovations that together alter clinical pathways and commercial models. Precision medicines and incretin-based biologics have expanded the therapeutic toolkit, while iterative improvements in insulin analog formulations and delivery devices have materially enhanced safety profiles and patient convenience. Simultaneously, the maturation of digital therapeutics, remote monitoring, and integrated care platforms is enabling more continuous management approaches, and these modalities are progressively woven into standard care algorithms.

In addition, payment and reimbursement models are shifting toward value-based contracting that ties reimbursement to outcomes rather than units dispensed. This change incentivizes manufacturers to demonstrate durable clinical benefits, improves alignment between providers and payers, and accelerates partnerships across the healthcare ecosystem. As a result, product development priorities now emphasize long-term cardiovascular and renal endpoints, adherence optimization, and patient-centered outcomes. Looking forward, convergence between pharmacology, device innovation, and data-driven care delivery will continue to redefine competitive advantage and the pathways through which patients access and remain on therapy.

Comprehensive analysis of how United States tariff policy adjustments in 2025 could reverberate through supply chains, pricing, and access pathways

Policy shifts in trade and tariff frameworks can introduce new frictions into global pharmaceutical supply chains, and the adjustments announced for 2025 have immediate operational and strategic implications. For organizations that rely on transnational sourcing of active pharmaceutical ingredients, primary packaging, or finished-dose manufacturing, tariff alterations can change cost structures, reallocate procurement priorities, and pressure timelines for scale-up. Consequently, supply-chain managers and procurement officers are increasingly evaluating supplier diversification, nearshoring, and inventory strategies to mitigate exposure to tariff-induced price volatility.

Moreover, changes in import duties can influence downstream pricing and payer negotiations, particularly in segments where competition is price-sensitive or where biosimilar entrants are accelerating therapeutic substitution. Reimbursement stakeholders may seek greater transparency on landed costs and supply risks as they negotiate formulary positioning and access pathways. From an operational perspective, manufacturers are also reassessing distribution agreements and contractual terms to preserve margin stability and maintain uninterrupted patient access. In sum, tariff policy adjustments function as a catalyst for more resilient sourcing strategies, tighter supplier collaboration, and increased emphasis on scenario planning to protect continuity of care.

Key segmentation insights decoding drug classes, patient populations, administration routes, therapy patterns, distribution paths and end-user demands

A nuanced segmentation framework is essential for interpreting therapeutic trends and competitive positioning across antidiabetic treatments. Based on Drug Class, the market is analyzed across Insulin and Oral Agents. Insulin is differentiated into Analog Insulin and Human Insulin, and the Analog Insulin segment is further examined across Long-Acting, Rapid-Acting, and Ultra-Long-Acting formulations to reflect their divergent clinical applications and device compatibilities. Meanwhile, the Oral Agents category is parsed into Biguanides, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT-2 Inhibitors, and Sulfonylureas, acknowledging distinct mechanisms of action and safety-efficacy trade-offs.

In addition to molecular class, segmentation by Patient Type separates clinical approaches for Gestational Diabetes, Prediabetes, Type 1 Diabetes, and Type 2 Diabetes, which clarifies differing therapeutic objectives and adherence patterns. The Route Of Administration axis distinguishes Oral and Parenteral delivery pathways, calling attention to formulation development and device strategy. Therapy Type compares Combination Therapy and Monotherapy to illuminate prescribing behavior and regimen complexity. Distribution Channel contrasts Offline and Online pathways, highlighting shifts in pharmacy access and digital dispensing models. Finally, End User classification across Clinics, Home Care, and Hospitals underscores where care delivery investments and patient education priorities should be concentrated.

Regional dynamics and nuanced market behavior across Americas, Europe Middle East & Africa, and Asia-Pacific emphasizing access and innovation drivers

Regional heterogeneity strongly influences therapeutic adoption, regulatory timelines, and reimbursement frameworks across the globe. In the Americas, health systems vary from integrated public-private models to predominantly private payer systems, and this variation affects formulary negotiation dynamics, routes to market, and the speed of innovative product uptake. Manufacturers operating in this region often prioritize real-world evidence generation and payer engagement to demonstrate value under diverse reimbursement conditions.

Across Europe, Middle East & Africa, regulatory harmonization and divergent purchasing mechanisms create both opportunities and complexities. In several European markets, centralized procurement and rigorous health-technology assessment processes necessitate robust clinical and economic evidence, while emerging markets in the Middle East and Africa may face constraints related to cold-chain logistics and access affordability. In contrast, the Asia-Pacific region comprises a mixture of highly developed regulatory ecosystems and rapidly expanding markets where demographic shifts and rising prevalence drive demand for scalable, accessible therapies. Consequently, strategies that account for regional infrastructure, local manufacturing potential, and tailored pricing approaches are essential for sustainable penetration and long-term patient access.

Strategic company landscapes revealing R&D priorities, collaboration models, and competitive positioning among leading pharmaceutical and biotech players

Leading companies in the antidiabetic domain are differentiating through a blend of deep clinical pipelines, strategic collaborations, and investments in patient-centric technologies. R&D priorities increasingly favor agents that demonstrate benefits beyond glycemic control, such as cardiovascular and renal protection, while development strategies also emphasize formulation enhancements that improve adherence and reduce treatment burden. Partnerships between pharmaceutical developers and digital health firms are accelerating the integration of remote monitoring, adherence interventions, and data analytics into therapeutic offerings, thereby creating bundled solutions that better address chronic disease management.

Competitive positioning is further shaped by geographic manufacturing footprints, supply-chain resilience, and capability in biologics development. Companies that combine robust clinical evidence generation with agile commercial models and payer engagement capabilities are best positioned to navigate complex reimbursement landscapes. In addition, smaller biotech firms and contract developers are contributing innovation in novel modalities and delivery technologies, often becoming acquisition targets or collaborators for larger organizations seeking to expand their therapeutic portfolios. Collectively, these strategic behaviors indicate a market environment where therapeutic differentiation, technical execution, and collaborative business models determine sustained leadership.

Actionable recommendations for industry leaders to accelerate adoption, strengthen supply resilience, and optimize patient-centric care pathways

Industry leaders should adopt a set of pragmatic actions to strengthen competitive resilience and to accelerate therapeutic impact across patient populations. First, integrate evidence-generation strategies with commercial planning so that clinical development programs are designed to support payer conversations and long-term outcomes assessment. By aligning clinical endpoints with real-world applicability, organizations can reduce time to reimbursement and improve formulary positioning. Second, diversify supply networks and invest in near-term contingency planning to mitigate risks associated with tariff changes, geopolitical shifts, and manufacturing disruptions.

Furthermore, prioritize patient-centered product design by investing in adherence-enhancing formulations and in digital tools that simplify disease management. Strengthening collaborations with providers and payers will facilitate outcome-based contracting and shared-risk agreements that align incentives across the care continuum. Finally, tailor regional go-to-market models to local infrastructure realities and regulatory expectations, and pursue strategic alliances with regional manufacturers or distributors to expedite access while optimizing cost structures. Together, these steps create a coherent roadmap for translating scientific innovation into measurable patient benefit and commercial sustainability.

Robust research methodology explaining data sources, analytical frameworks, validation processes, and steps taken to ensure methodological rigor

The research methodology underpinning this analysis combines multi-source evidence synthesis, expert validation, and iterative analytical review to ensure rigor and relevance. Primary inputs include peer-reviewed clinical literature, regulatory guidance documents, and publicly available clinical trial registries, which are synthesized to map therapeutic mechanisms, safety profiles, and evolving endpoint priorities. These sources are complemented by industry disclosures and company filings to understand strategic initiatives and technology investments.

Analytical frameworks incorporate qualitative expert interviews and scenario-based risk assessment to evaluate supply-chain vulnerabilities and policy impacts. Throughout the process, internal validation steps cross-reference clinical findings with regulatory trends and real-world evidence to ensure consistency. Sensitivity analyses and triangulation are applied to reconcile disparate inputs, and methodological transparency is maintained through detailed documentation of data sources, inclusion criteria, and analytical assumptions. This approach provides stakeholders with a defensible basis for strategic decision-making while remaining adaptable to new data as it emerges.

Conclusive synthesis that integrates clinical trends, policy impacts, segmentation insights, and forward-looking implications for stakeholders

This synthesis integrates clinical innovation, policy developments, segmentation clarity, and regional nuance to form a coherent picture of contemporary antidiabetic therapeutics. Emerging biologics and next-generation insulin formulations are reshaping treatment paradigms, while digital health integration and value-based reimbursement models are changing how evidence is generated and how treatments are procured. At the same time, tariff and trade policy shifts act as operational stress tests that expose supply-chain vulnerabilities and compel strategic adjustments in sourcing and distribution.

Collectively, these forces indicate that long-term success will favor organizations that combine scientific differentiation with operational agility and payer-centered evidence strategies. To navigate this landscape, stakeholders must prioritize patient-centric design, resilient procurement frameworks, and targeted regional approaches that account for regulatory and infrastructural variability. In doing so, they can better ensure sustained access to effective therapies and realize the clinical and economic benefits of contemporary diabetes care.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antidiabetic Drugs Market, by Drug Class

  • 8.1. Insulin
    • 8.1.1. Analog Insulin
      • 8.1.1.1. Long-Acting
      • 8.1.1.2. Rapid-Acting
      • 8.1.1.3. Ultra-Long-Acting
    • 8.1.2. Human Insulin
  • 8.2. Oral Agents
    • 8.2.1. Biguanides
    • 8.2.2. DPP-4 Inhibitors
    • 8.2.3. GLP-1 Receptor Agonists
    • 8.2.4. SGLT-2 Inhibitors
    • 8.2.5. Sulfonylureas

9. Antidiabetic Drugs Market, by Patient Type

  • 9.1. Gestational Diabetes
  • 9.2. Prediabetes
  • 9.3. Type 1 Diabetes
  • 9.4. Type 2 Diabetes

10. Antidiabetic Drugs Market, by Route Of Administration

  • 10.1. Oral
  • 10.2. Parenteral

11. Antidiabetic Drugs Market, by Therapy Type

  • 11.1. Combination Therapy
  • 11.2. Monotherapy

12. Antidiabetic Drugs Market, by Distribution Channel

  • 12.1. Offline
  • 12.2. Online

13. Antidiabetic Drugs Market, by End User

  • 13.1. Clinics
  • 13.2. Home Care
  • 13.3. Hospitals

14. Antidiabetic Drugs Market, by Region

  • 14.1. Americas
    • 14.1.1. North America
    • 14.1.2. Latin America
  • 14.2. Europe, Middle East & Africa
    • 14.2.1. Europe
    • 14.2.2. Middle East
    • 14.2.3. Africa
  • 14.3. Asia-Pacific

15. Antidiabetic Drugs Market, by Group

  • 15.1. ASEAN
  • 15.2. GCC
  • 15.3. European Union
  • 15.4. BRICS
  • 15.5. G7
  • 15.6. NATO

16. Antidiabetic Drugs Market, by Country

  • 16.1. United States
  • 16.2. Canada
  • 16.3. Mexico
  • 16.4. Brazil
  • 16.5. United Kingdom
  • 16.6. Germany
  • 16.7. France
  • 16.8. Russia
  • 16.9. Italy
  • 16.10. Spain
  • 16.11. China
  • 16.12. India
  • 16.13. Japan
  • 16.14. Australia
  • 16.15. South Korea

17. United States Antidiabetic Drugs Market

18. China Antidiabetic Drugs Market

19. Competitive Landscape

  • 19.1. Market Concentration Analysis, 2025
    • 19.1.1. Concentration Ratio (CR)
    • 19.1.2. Herfindahl Hirschman Index (HHI)
  • 19.2. Recent Developments & Impact Analysis, 2025
  • 19.3. Product Portfolio Analysis, 2025
  • 19.4. Benchmarking Analysis, 2025
  • 19.5. Abbott Laboratories
  • 19.6. Alkem Laboratories Ltd.
  • 19.7. Aristo Pharmaceuticals Pvt. Ltd.
  • 19.8. Astellas Pharma Inc.
  • 19.9. AstraZeneca PLC
  • 19.10. Biocon Limited
  • 19.11. Boehringer Ingelheim International GmbH
  • 19.12. Cadila Pharmaceuticals Limited
  • 19.13. Cipla Limited
  • 19.14. Dr. Reddy's Laboratories
  • 19.15. Eli Lilly and Company
  • 19.16. F. Hoffmann-La Roche Ltd.
  • 19.17. GlaxoSmithKline PLC
  • 19.18. Glenmark Pharmaceuticals Ltd.
  • 19.19. Halozyme Therapeutics, Inc.
  • 19.20. Johnson & Johnson Services, Inc.
  • 19.21. Mankind Pharma Ltd.
  • 19.22. Merck KGaA
  • 19.23. Novo Nordisk A/S
  • 19.24. Oramed Pharmaceuticals Inc.
  • 19.25. Pfizer Inc.
  • 19.26. PHC Holdings Corporation
  • 19.27. Sanofi S.A.
  • 19.28. Takeda Pharmaceutical Company Limited
  • 19.29. Teva Pharmaceutical Industries Ltd.
  • 19.30. Tonghua Dongbao Pharmaceutical Co., Ltd.

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIDIABETIC DRUGS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTIDIABETIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 13. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 14. CHINA ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY LONG-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY RAPID-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ULTRA-LONG-ACTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ULTRA-LONG-ACTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ULTRA-LONG-ACTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HUMAN INSULIN, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HUMAN INSULIN, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HUMAN INSULIN, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY BIGUANIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DPP-4 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GLP-1 RECEPTOR AGONISTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SGLT-2 INHIBITORS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SULFONYLUREAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SULFONYLUREAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY SULFONYLUREAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GESTATIONAL DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PREDIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PREDIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PREDIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 1 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY TYPE 2 DIABETES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COMBINATION THERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY MONOTHERAPY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY MONOTHERAPY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY OFFLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY OFFLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY OFFLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ONLINE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ONLINE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY CLINICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY CLINICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY CLINICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOME CARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOME CARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOME CARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 87. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 88. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 89. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 90. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 91. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 92. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 94. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 96. AMERICAS ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 97. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 98. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 99. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 100. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 101. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 102. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 104. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 106. NORTH AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 109. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 110. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 111. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 112. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 114. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 115. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 116. LATIN AMERICA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 118. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 119. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPE, MIDDLE EAST & AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 132. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 133. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 134. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 135. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 136. EUROPE ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 145. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 146. MIDDLE EAST ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 147. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 148. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 149. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 150. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 151. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 152. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 154. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 156. AFRICA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 158. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 159. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 160. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 161. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 162. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 163. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 164. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 165. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 166. ASIA-PACIFIC ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 168. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 169. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 170. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 171. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 172. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 173. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 174. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 175. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 177. ASEAN ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 178. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 179. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 180. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 181. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 182. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 183. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 184. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 185. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 186. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 187. GCC ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPEAN UNION ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 198. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 199. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 200. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 201. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 202. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 203. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 205. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 207. BRICS ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 208. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 209. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 210. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 211. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 212. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 213. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 214. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 215. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 216. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 217. G7 ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 218. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 219. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 220. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 221. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 222. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 223. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 224. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 225. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 227. NATO ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. GLOBAL ANTIDIABETIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 229. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 230. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 231. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 232. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 233. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 234. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 236. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 237. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 238. UNITED STATES ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 239. CHINA ANTIDIABETIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 240. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2032 (USD MILLION)
  • TABLE 241. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY INSULIN, 2018-2032 (USD MILLION)
  • TABLE 242. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY ANALOG INSULIN, 2018-2032 (USD MILLION)
  • TABLE 243. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY ORAL AGENTS, 2018-2032 (USD MILLION)
  • TABLE 244. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY PATIENT TYPE, 2018-2032 (USD MILLION)
  • TABLE 245. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 246. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY THERAPY TYPE, 2018-2032 (USD MILLION)
  • TABLE 247. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2032 (USD MILLION)
  • TABLE 248. CHINA ANTIDIABETIC DRUGS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)